| Revenue growth | 12.3% YoY for FY26; 23.5% YoY for Q4FY26. |
|---|---|
| Margins | FY26 Gross Margin at 26.2%, up 180bps YoY. |
| Management confidence | High; emphasizing profitability of older stores and cluster leadership. |
Growth
FY26 Revenue grew 12.3% to ₹68,925m; PAT increased 46.2% to ₹2,196m. Q4FY26 revenue up 23.5% YoY.
Outlook
Targeting deeper penetration in existing clusters; extending <2 hour delivery; growing private label basket beyond 1550+ SKUs.
Risks
Expansion of new stores (<12 months) dragging consolidated margins initially; intense competition in omni-channel pharmacy retail.
Earnings Call filed with BSE, NSE: MEDPLUS. Summary written with AI assistance from the document.
Medplus Health Services Ltd: key numbers
- Share price
- ₹654.90
- Market cap
- ₹7,868 Cr
- Revenue (annual)
- ₹6,892 Cr
- Net profit (annual)
- ₹219.7 Cr
- P/E (TTM)
- 37.4×Sector 57.8×
- Promoter holding
- 40.19%-0.03% QoQ
- FII holding
- 14.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medplus Health Services Ltd
All →Medplus Health Services Adverse Business Impact
Medplus Health Services' subsidiary, Optival Health Solutions, faced a three-day drug license suspension at a store by the Drugs Control Administration, impacting operations by ₹0.01 Crore.
- Value
- ₹0.01 Cr
- From
- Drugs Control Administration, Haveri Circle, Karnataka
Medplus Health Services Legal & Regulatory
MedPlus Health Services' subsidiary, Optival Health Solutions, received a one-day drug license suspension from the Drugs Control Administration for a store in Telangana due to non-compliance.
- Value
- ₹0.01 Cr
Medplus Health Services Legal & Regulatory
Medplus Health Services' subsidiary, Optival Health, received a 7-day drug license suspension in Andhra Pradesh and stay orders for previous suspensions in Maharashtra.
- Value
- ₹0.02 Cr
Medplus Health Services Legal & Regulatory
Medplus Health Services disclosed that regulatory authorities suspended the drug licenses of five subsidiary stores for 3 to 7 days. The expected financial impact is ₹0.10 Crore.
- Value
- ₹0.10 Cr
Medplus Health Services Adverse Business Impact
Medplus Health Services reported a 7-day drug license suspension for a subsidiary store, impacting its operations with an estimated financial loss of ₹0.02 Crore.
- Value
- ₹0.02 Cr
- Execution
- 7 days
Medplus Health Services Adverse Business Impact
Medplus Health Services' subsidiary, Optival Health Solutions, faced drug license suspensions for two stores from regulatory authorities, causing a total financial impact of Rs 0.0961 Crore.
- Value
- ₹0.10 Cr
- Execution
- 5 to 15 days